Methyclothiazide

Generic name: Pronounced as (meth i kloe thye' a zide)
Brand names
  • Aquatensen®
  • Enduron®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 08/15/2017

Methyclothiazide is used to treat high blood pressure. Methyclothiazide is also used to treat edema (fluid retention; excess fluid held in body tissues) caused by various medical problems, including heart, kidney, and liver disease and to treat edema caused by using certain medications including estrogen and corticosteroids. Methyclothiazide is in a class of medications called diuretics ('water pills'). It works by causing the kidneys to get rid of unneeded water and salt from the body into the urine.

High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.

Methyclothiazide comes as a tablet to take by mouth. It usually is taken once a day in the morning. Take methyclothiazide around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take methyclothiazide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Methyclothiazide controls high blood pressure and edema but does not cure these conditions. Continue to take methyclothiazide even if you feel well. Do not stop taking methyclothiazide without talking to your doctor.

Methyclothiazide may also be used to treat patients with diabetes insipidus and certain electrolyte disturbances and to prevent kidney stones in patients with high levels of calcium in their blood. Talk to your doctor about the possible risks of using this medicine for your condition.

This medicine is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking methyclothiazide,

  • tell your doctor and pharmacist if you are allergic to methyclothiazide, sulfonamide medications, any other medications, or any of the ingredients in methyclothiazide tablets. Ask your pharmacist or check the patient information for a list of the ingredients.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: barbiturates such as phenobarbital and secobarbital (Seconal); corticosteroids such as betamethasone (Celestone), budesonide (Entocort), cortisone (Cortone), dexamethasone (Decadron, Dexpak, Dexasone, others), fludrocortisone (Florinef), hydrocortisone (Cortef, Hydrocortone), methylprednisolone (Medrol, Meprolone, others), prednisolone (Prelone, others), prednisone (Rayos), and triamcinolone (Aristocort, Azmacort); corticotropin (ACTH, H.P., Acthar Gel); insulin and oral medications for diabetes; digoxin (Lanoxin), lithium (Lithobid), medications for high blood pressure, and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin, others) and naproxen (Aleve, Naprosyn, others). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have kidney disease. Your doctor may tell you not to take methyclothiazide.

  • tell your doctor if you have or have ever had asthma, diabetes, gout, high cholesterol, systemic lupus erythematosus (SLE, a chronic inflammatory condition), or liver disease.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking methyclothiazide, call your doctor immediately.

  • plan to avoid unnecessary or prolonged exposure to sunlight and to wear protective clothing, sunglasses, and sunscreen. Methyclothiazide may make your skin sensitive to sunlight.

  • you should know that methyclothiazide may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. This is more common when you first start taking methyclothiazide. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up. Alcohol can add to these side effects.

If your doctor prescribes a low-salt or low-sodium diet, or to eat or drink increased amounts of potassium-rich foods (e.g., bananas, prunes, raisins, and orange juice) in your diet, follow these instructions carefully.

Take the missed dose as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Tell your doctor if any of these symptoms are severe or do not go away:

    • frequent urination

    • stomach pain

    • upset stomach

    • constipation

    • diarrhea

    • loss of appetite

    • headache

    • blurred vision

  • Some side effects can be serious. If you have any of these symptoms, call your doctor immediately or seek emergency medical treatment:

    • dry mouth; thirst; nausea; vomiting; weakness, tiredness; drowsiness; restlessness; confusion; muscle weakness, pain, or cramps; fast heartbeat and other signs of dehydration and electrolyte imbalance

    • yellowing of the eyes and skin

    • fever

    • blisters or peeling skin

    • difficulty breathing or swallowing

    • rash

    • itching

    • hives

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medicine in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Keep all appointments with your doctor and the laboratory. Your blood pressure should be checked regularly, and blood tests should be done occasionally.

Before having any laboratory test, tell your doctor and the laboratory personnel that you are taking methyclothiazide.

Do not let anyone else take your medicine. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

  • Diutensen-R® (containing Methyclothiazide, Reserpine)
  • Enduronyl® (containing Deserpidine, Methyclothiazide)

Drug Interaction
Repaglinide Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Methyclothiazide.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Methyclothiazide.
Bisacodyl Bisacodyl The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bisacodyl.
Calcium Carbonate Calcium Carbonate Methyclothiazide may decrease the excretion rate of Calcium carbonate which could result in a higher serum level.
Candesartan Candesartan The therapeutic efficacy of Candesartan can be increased when used in combination with Methyclothiazide.
Cilostazol Cilostazol Methyclothiazide may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.
Diphenoxylate Diphenoxylate The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diphenoxylate.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) Methyclothiazide may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.
Fenofibrate Fenofibrate Methyclothiazide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.
Guanfacine Guanfacine The therapeutic efficacy of Guanfacine can be increased when used in combination with Methyclothiazide.
Magnesium Hydroxide Magnesium Hydroxide The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium hydroxide.
Magnesium Oxide Magnesium Oxide The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium oxide.
Miglitol Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Methyclothiazide.
Mycophenolate Mycophenolate Methyclothiazide may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.
Olsalazine Olsalazine The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olsalazine.
Paregoric Paregoric The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Morphine.
Penbutolol Penbutolol The therapeutic efficacy of Acebutolol can be increased when used in combination with Methyclothiazide.
Pentazocine Pentazocine The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pentazocine.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Polyethylene glycol.
Potassium Potassium Methyclothiazide may increase the excretion rate of Potassium cation which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone Prednisone The risk or severity of electrolyte imbalance can be increased when Prednisone is combined with Methyclothiazide.
Psyllium Psyllium The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Plantago seed.
Ranitidine Ranitidine Methyclothiazide may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.
Reserpine Reserpine The therapeutic efficacy of Reserpine can be increased when used in combination with Methyclothiazide.
Rizatriptan Rizatriptan Methyclothiazide may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.
Sumatriptan Sumatriptan Methyclothiazide may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy.
Tacrolimus Tacrolimus The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Tacrolimus.
Tizanidine Tizanidine The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tizanidine.
Triamcinolone Triamcinolone The risk or severity of electrolyte imbalance can be increased when Triamcinolone is combined with Methyclothiazide.
Ampicillin Injection Ampicillin Injection Methyclothiazide may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.
Doxycycline Injection Doxycycline Injection Methyclothiazide may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.
Fluconazole Injection Fluconazole Injection Methyclothiazide may increase the excretion rate of Fluconazole which could result in a lower serum level and potentially a reduction in efficacy.
Hydromorphone Injection Hydromorphone Injection The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Hydromorphone.
Interferon Beta-1b Injection Interferon Beta-1b Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon beta-1b.
Interferon Gamma-1b Injection Interferon Gamma-1b Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon gamma-1b.
Levofloxacin Injection Levofloxacin Injection Methyclothiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.
Meperidine Injection Meperidine Injection The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meperidine.
Methylprednisolone Injection Methylprednisolone Injection The risk or severity of electrolyte imbalance can be increased when Methylprednisolone is combined with Methyclothiazide.
Metoclopramide Injection Metoclopramide Injection Methyclothiazide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Morphine Injection Morphine Injection The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Morphine.
Vancomycin Injection Vancomycin Injection Methyclothiazide may increase the excretion rate of Vancomycin which could result in a lower serum level and potentially a reduction in efficacy.
Zidovudine Injection Zidovudine Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Zidovudine.
Altretamine Altretamine Amphetamine may increase the orthostatic hypotensive activities of Methyclothiazide.
Cyclosporine Cyclosporine The risk or severity of renal failure can be increased when Methyclothiazide is combined with Cyclosporine.
Enoxaparin Injection Enoxaparin Injection The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Methyclothiazide.
Torsemide Torsemide The therapeutic efficacy of Torasemide can be increased when used in combination with Methyclothiazide.
Olanzapine Olanzapine The serum concentration of Methyclothiazide can be increased when it is combined with Olanzapine.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Methyclothiazide is combined with Dofetilide.
Eprosartan Eprosartan The therapeutic efficacy of Eprosartan can be increased when used in combination with Methyclothiazide.
Meloxicam Meloxicam The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meloxicam.
Oxcarbazepine Oxcarbazepine The risk or severity of hyponatremia can be increased when Methyclothiazide is combined with Oxcarbazepine.
Pantoprazole Pantoprazole Methyclothiazide may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.
Sevelamer Sevelamer Sevelamer can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Telmisartan Telmisartan The therapeutic efficacy of Telmisartan can be increased when used in combination with Methyclothiazide.
Temozolomide Temozolomide Methyclothiazide may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.
Zaleplon Zaleplon Methyclothiazide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.
Desloratadine Desloratadine The serum concentration of Methyclothiazide can be increased when it is combined with Desloratadine.
Linezolid Linezolid Linezolid may increase the orthostatic hypotensive activities of Methyclothiazide.
Pentosan Polysulfate Pentosan Polysulfate The therapeutic efficacy of Pentosan polysulfate can be decreased when used in combination with Methyclothiazide.
Glycopyrrolate Glycopyrrolate The serum concentration of Methyclothiazide can be increased when it is combined with Glycopyrronium.
Perindopril Perindopril The therapeutic efficacy of Perindopril can be increased when used in combination with Methyclothiazide.
Tenofovir Tenofovir Methyclothiazide may increase the excretion rate of Tenofovir which could result in a lower serum level and potentially a reduction in efficacy.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Choline magnesium trisalicylate.
Sirolimus Sirolimus The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Sirolimus.
Epinephrine Injection Epinephrine Injection The risk or severity of Cardiac Arrhythmia can be increased when Epinephrine is combined with Methyclothiazide.
Epirubicin Epirubicin The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Epirubicin.
Eplerenone Eplerenone The therapeutic efficacy of Eplerenone can be increased when used in combination with Methyclothiazide.
Escitalopram Escitalopram The risk or severity of hyponatremia can be increased when Escitalopram is combined with Methyclothiazide.
Olmesartan Olmesartan The therapeutic efficacy of Olmesartan can be increased when used in combination with Methyclothiazide.
Zonisamide Zonisamide Methyclothiazide may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Aripiprazole Aripiprazole Aripiprazole may increase the hypotensive activities of Methyclothiazide.
Atomoxetine Atomoxetine Methyclothiazide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.
Almotriptan Almotriptan Methyclothiazide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Polyethylene glycol.
Vardenafil Vardenafil The risk or severity of hypotension can be increased when Vardenafil is combined with Methyclothiazide.
Emtricitabine Emtricitabine Methyclothiazide may increase the excretion rate of Emtricitabine which could result in a lower serum level and potentially a reduction in efficacy.
Memantine Memantine Methyclothiazide may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.
Tegaserod Tegaserod The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tegaserod.
Tadalafil Tadalafil The therapeutic efficacy of Tadalafil can be increased when used in combination with Methyclothiazide.
Apomorphine Injection Apomorphine Injection The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Apomorphine.
Duloxetine Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Methyclothiazide is combined with Duloxetine.
Tinidazole Tinidazole Methyclothiazide may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.
Trospium Trospium The serum concentration of Methyclothiazide can be increased when it is combined with Trospium.
Bosentan Bosentan The therapeutic efficacy of Bosentan can be increased when used in combination with Methyclothiazide.
Cefditoren Cefditoren Methyclothiazide may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.
Cyanocobalamin Injection Cyanocobalamin Injection Methyclothiazide may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Eszopiclone Eszopiclone Methyclothiazide may increase the excretion rate of Eszopiclone which could result in a lower serum level and potentially a reduction in efficacy.
Ganciclovir Ganciclovir Methyclothiazide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Methyclothiazide.
Ribavirin Ribavirin Methyclothiazide may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.
Solifenacin Solifenacin The serum concentration of Methyclothiazide can be increased when it is combined with Solifenacin.
Valganciclovir Valganciclovir Methyclothiazide may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.
Dextroamphetamine Dextroamphetamine Amphetamine may increase the orthostatic hypotensive activities of Methyclothiazide.
Peginterferon Alfa-2a Injection Peginterferon Alfa-2a Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Peginterferon alfa-2b.
Pramlintide Injection Pramlintide Injection The therapeutic efficacy of Pramlintide can be decreased when used in combination with Methyclothiazide.
Exenatide Injection Exenatide Injection The therapeutic efficacy of Exenatide can be decreased when used in combination with Methyclothiazide.
Isocarboxazid Isocarboxazid Isocarboxazid may increase the orthostatic hypotensive activities of Methyclothiazide.
Ramelteon Ramelteon Methyclothiazide may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.
Darifenacin Darifenacin The serum concentration of Methyclothiazide can be increased when it is combined with Darifenacin.
Fentanyl Fentanyl The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fentanyl.
Pregabalin Pregabalin Methyclothiazide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Methyclothiazide.
Ranolazine Ranolazine Methyclothiazide may increase the excretion rate of Ranolazine which could result in a lower serum level and potentially a reduction in efficacy.
Rasagiline Rasagiline Rasagiline may increase the orthostatic hypotensive activities of Methyclothiazide.
Imatinib Imatinib The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Imatinib.
Sitagliptin Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methyclothiazide.
Varenicline Varenicline Methyclothiazide may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.
Albuterol Albuterol Salbutamol may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Paliperidone Paliperidone Methyclothiazide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Bortezomib Bortezomib The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Bortezomib.
Clofarabine Injection Clofarabine Injection Methyclothiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Methyclothiazide.
Lubiprostone Lubiprostone The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lubiprostone.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Oxaliplatin.
Rituximab Injection Rituximab Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Rituximab.
Aliskiren Aliskiren The therapeutic efficacy of Aliskiren can be increased when used in combination with Methyclothiazide.
Pemetrexed Injection Pemetrexed Injection Methyclothiazide may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.
Nabilone Nabilone The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nabilone.
Vorinostat Vorinostat The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Vorinostat.
Sorafenib Sorafenib Methyclothiazide may increase the excretion rate of Sorafenib which could result in a lower serum level and potentially a reduction in efficacy.
Sunitinib Sunitinib The therapeutic efficacy of Sunitinib can be decreased when used in combination with Methyclothiazide.
Levocetirizine Levocetirizine Methyclothiazide may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.
Pegaptanib Injection Pegaptanib Injection Methyclothiazide may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.
Dasatinib Dasatinib The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Dasatinib.
Azacitidine Injection Azacitidine Injection Methyclothiazide may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.
Paclitaxel (with polyoxyethylated castor oil) Injection Paclitaxel (with polyoxyethylated castor oil) Injection The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Castor oil.
Temsirolimus Temsirolimus The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Temsirolimus.
Nelarabine Injection Nelarabine Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Nelarabine.
Lenalidomide Lenalidomide Methyclothiazide may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Nilotinib Nilotinib The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Nilotinib.
Toremifene Toremifene The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Toremifene.
Bexarotene Bexarotene The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Bexarotene.
Budesonide Budesonide The risk or severity of electrolyte imbalance can be increased when Budesonide is combined with Methyclothiazide.
Chloramphenicol Injection Chloramphenicol Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Chloramphenicol.
Decitabine Injection Decitabine Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Decitabine.
Desmopressin Desmopressin Methyclothiazide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
Doripenem Injection Doripenem Injection Methyclothiazide may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.
Arsenic Trioxide Injection Arsenic Trioxide Injection Methyclothiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.
Mitoxantrone Injection Mitoxantrone Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Mitoxantrone.
Desvenlafaxine Desvenlafaxine The risk or severity of hyponatremia can be increased when Desvenlafaxine is combined with Methyclothiazide.
Cevimeline Cevimeline Methyclothiazide may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.
Nebivolol Nebivolol The therapeutic efficacy of Nebivolol can be increased when used in combination with Methyclothiazide.
Tretinoin Tretinoin The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tretinoin.
Bendamustine Injection Bendamustine Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Bendamustine.
Certolizumab Injection Certolizumab Injection Methyclothiazide may increase the excretion rate of Certolizumab pegol which could result in a lower serum level and potentially a reduction in efficacy.
Ixabepilone Injection Ixabepilone Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ixabepilone.
Irinotecan Injection Irinotecan Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Irinotecan.
Daptomycin Injection Daptomycin Injection Methyclothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Methylnaltrexone Injection Methylnaltrexone Injection Methyclothiazide may increase the excretion rate of Methylnaltrexone which could result in a lower serum level and potentially a reduction in efficacy.
Alemtuzumab Injection (Chronic Lymphocytic Leukemia) Alemtuzumab Injection (Chronic Lymphocytic Leukemia) The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Alemtuzumab.
Midazolam Midazolam Methyclothiazide may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.
Naltrexone Injection Naltrexone Injection The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naltrexone.
Dexrazoxane Injection Dexrazoxane Injection Methyclothiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Ibritumomab Injection Ibritumomab Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ibritumomab tiuxetan.
Milnacipran Milnacipran The risk or severity of hyponatremia can be increased when Milnacipran is combined with Methyclothiazide.
Plerixafor Injection Plerixafor Injection Methyclothiazide may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.
Sodium Phosphate Sodium Phosphate Methyclothiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.
Febuxostat Febuxostat The therapeutic efficacy of Febuxostat can be decreased when used in combination with Methyclothiazide.
Fesoterodine Fesoterodine Fesoterodine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Betaxolol Betaxolol The therapeutic efficacy of Betaxolol can be increased when used in combination with Methyclothiazide.
Prasugrel Prasugrel Methyclothiazide may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.
Everolimus Everolimus The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Everolimus.
Pralatrexate Injection Pralatrexate Injection Methyclothiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Palonosetron Injection Palonosetron Injection Methyclothiazide may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.
Saxagliptin Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methyclothiazide.
Telavancin Injection Telavancin Injection Methyclothiazide may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.
Tapentadol Tapentadol The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tapentadol.
Topotecan Topotecan Methyclothiazide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Rasburicase Injection Rasburicase Injection The therapeutic efficacy of Rasburicase can be decreased when used in combination with Methyclothiazide.
Oxymorphone Oxymorphone The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxymorphone.
Dabigatran Dabigatran The therapeutic efficacy of Dabigatran can be decreased when used in combination with Methyclothiazide.
Liraglutide Injection Liraglutide Injection The therapeutic efficacy of Liraglutide can be decreased when used in combination with Methyclothiazide.
Dalfampridine Dalfampridine Methyclothiazide may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.
Eribulin Injection Eribulin Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Eribulin.
Cabazitaxel Injection Cabazitaxel Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Cabazitaxel.
Pegloticase Injection Pegloticase Injection The therapeutic efficacy of Pegloticase can be decreased when used in combination with Methyclothiazide.
Acetaminophen Injection Acetaminophen Injection Methyclothiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.
Ipilimumab Injection Ipilimumab Injection Methyclothiazide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.
Denileukin Diftitox Injection Denileukin Diftitox Injection Aldesleukin may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Terbutaline Injection Terbutaline Injection Terbutaline may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Azilsartan Azilsartan Methyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Azilsartan medoxomil.
Busulfan Injection Busulfan Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Busulfan.
Roflumilast Roflumilast Methyclothiazide may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.
Linagliptin Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Methyclothiazide.
Cyclophosphamide Injection Cyclophosphamide Injection The risk or severity of granulocytopenia can be increased when Methyclothiazide is combined with Cyclophosphamide.
Rivaroxaban Rivaroxaban Methyclothiazide may increase the excretion rate of Rivaroxaban which could result in a lower serum level and potentially a reduction in efficacy.
Ticagrelor Ticagrelor The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Methyclothiazide.
Ruxolitinib Ruxolitinib Methyclothiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Clobazam Clobazam Methyclothiazide may increase the excretion rate of Clobazam which could result in a lower serum level and potentially a reduction in efficacy.
Deferiprone Deferiprone Methyclothiazide may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.
Melphalan Injection Melphalan Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Melphalan.
Naloxone Injection Naloxone Injection Naloxone may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Ambrisentan Ambrisentan The therapeutic efficacy of Ambrisentan can be increased when used in combination with Methyclothiazide.
Fondaparinux Injection Fondaparinux Injection Methyclothiazide may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.
Carfilzomib Injection Carfilzomib Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Carfilzomib.
Iloprost Iloprost The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Iloprost.
Enzalutamide Enzalutamide Methyclothiazide may increase the excretion rate of Enzalutamide which could result in a lower serum level and potentially a reduction in efficacy.
Mirabegron Mirabegron Methyclothiazide may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
Bosutinib Bosutinib The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Bosutinib.
Corticotropin, Repository Injection Corticotropin, Repository Injection The risk or severity of electrolyte imbalance can be increased when Corticotropin is combined with Methyclothiazide.
Linaclotide Linaclotide The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Linaclotide.
Lorcaserin Lorcaserin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Methyclothiazide.
Teduglutide Injection Teduglutide Injection Methyclothiazide may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.
Tofacitinib Tofacitinib The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Tofacitinib.
Alogliptin Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Methyclothiazide.
Ponatinib Ponatinib The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ponatinib.
Pomalidomide Pomalidomide Methyclothiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Trastuzumab emtansine.
Apixaban Apixaban The therapeutic efficacy of Apixaban can be decreased when used in combination with Methyclothiazide.
Canagliflozin Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methyclothiazide.
Methazolamide Methazolamide The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methazolamide.
Trametinib Trametinib Methyclothiazide may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.
Levomilnacipran Levomilnacipran The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Methyclothiazide.
Ertapenem Injection Ertapenem Injection Methyclothiazide may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.
Vortioxetine Vortioxetine Methyclothiazide may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.
Ibrutinib Ibrutinib The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ibrutinib.
Avanafil Avanafil The risk or severity of hypotension can be increased when Avanafil is combined with Methyclothiazide.
Ketorolac Injection Ketorolac Injection The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketorolac.
Obinutuzumab Injection Obinutuzumab Injection The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Obinutuzumab.
Sofosbuvir Sofosbuvir Methyclothiazide may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy.
Dapagliflozin Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Methyclothiazide.
Apremilast Apremilast Methyclothiazide may increase the excretion rate of Apremilast which could result in a lower serum level and potentially a reduction in efficacy.
Droxidopa Droxidopa The risk or severity of Cardiac Arrhythmia can be increased when Droxidopa is combined with Methyclothiazide.
Albiglutide Injection Albiglutide Injection The therapeutic efficacy of Albiglutide can be decreased when used in combination with Methyclothiazide.
Belinostat Injection Belinostat Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Belinostat.
Testosterone Injection Testosterone Injection Methyclothiazide may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.
Empagliflozin Empagliflozin Methyclothiazide may increase the diuretic activities of Empagliflozin.
Vorapaxar Vorapaxar The therapeutic efficacy of Vorapaxar can be decreased when used in combination with Methyclothiazide.
Hydrocodone Hydrocodone The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Hydrocodone.
Dulaglutide Injection Dulaglutide Injection The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methyclothiazide.
Edoxaban Edoxaban Methyclothiazide may increase the excretion rate of Edoxaban which could result in a lower serum level and potentially a reduction in efficacy.
Peginterferon Beta-1a Injection Peginterferon Beta-1a Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Peginterferon beta-1a.
Olaparib Olaparib The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Olaparib.
Blinatumomab Injection Blinatumomab Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Blinatumomab.
Methamphetamine Methamphetamine Methyclothiazide may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Tasimelteon Tasimelteon Methyclothiazide may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.
Riociguat Riociguat The therapeutic efficacy of Riociguat can be increased when used in combination with Methyclothiazide.
Risperidone Injection Risperidone Injection Methyclothiazide may increase the hypotensive activities of Risperidone.
Palbociclib Palbociclib The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Palbociclib.
Insulin Human Inhalation Insulin Human Inhalation The therapeutic efficacy of Insulin human can be decreased when used in combination with Methyclothiazide.
Dinutuximab Injection Dinutuximab Injection The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dinutuximab.
Haloperidol Injection Haloperidol Injection Methyclothiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Ivabradine Ivabradine The risk or severity of Cardiac Arrhythmia can be increased when Methyclothiazide is combined with Ivabradine.
Amiloride Amiloride The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amiloride.
Macitentan Macitentan The therapeutic efficacy of Macitentan can be increased when used in combination with Methyclothiazide.
Prednisolone Prednisolone The risk or severity of electrolyte imbalance can be increased when Prednisolone is combined with Methyclothiazide.
Ziprasidone Injection Ziprasidone Injection The serum concentration of Methyclothiazide can be increased when it is combined with Ziprasidone.
Penicillin G Procaine Injection Penicillin G Procaine Injection Methyclothiazide may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.
Eluxadoline Eluxadoline The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Methyclothiazide.
Trabectedin Injection Trabectedin Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Trabectedin.
Ixazomib Ixazomib Methyclothiazide may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.
Lesinurad Lesinurad The therapeutic efficacy of Lesinurad can be decreased when used in combination with Methyclothiazide.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection The risk or severity of electrolyte imbalance can be increased when Methyclothiazide is combined with Amphotericin B.
Dexamethasone Injection Dexamethasone Injection The risk or severity of electrolyte imbalance can be increased when Dexamethasone is combined with Methyclothiazide.
Defibrotide Injection Defibrotide Injection The therapeutic efficacy of Defibrotide can be decreased when used in combination with Methyclothiazide.
Brivaracetam Injection Brivaracetam Injection Methyclothiazide may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.
Selexipag Selexipag The therapeutic efficacy of Selexipag can be increased when used in combination with Methyclothiazide.
Diphenhydramine Injection Diphenhydramine Injection The serum concentration of Methyclothiazide can be increased when it is combined with Diphenhydramine.
Calcifediol Calcifediol The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Calcifediol.
Ergocalciferol Ergocalciferol The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Ergocalciferol.
Doxercalciferol Doxercalciferol The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Doxercalciferol.
Furosemide Injection Furosemide Injection The therapeutic efficacy of Furosemide can be increased when used in combination with Methyclothiazide.
Lixisenatide Injection Lixisenatide Injection The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Methyclothiazide.
Doxepin (Insomnia) Doxepin (Insomnia) Doxepin may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Plecanatide Plecanatide The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Plecanatide.
Deutetrabenazine Deutetrabenazine Methyclothiazide may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.
Valbenazine Valbenazine Methyclothiazide may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.
Deflazacort Deflazacort The risk or severity of electrolyte imbalance can be increased when Deflazacort is combined with Methyclothiazide.
Safinamide Safinamide Safinamide may increase the orthostatic hypotensive activities of Methyclothiazide.
Naldemedine Naldemedine Methyclothiazide may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.
Benznidazole Benznidazole Methyclothiazide may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.
Delafloxacin Delafloxacin Methyclothiazide may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy.
Betrixaban Betrixaban The therapeutic efficacy of Betrixaban can be decreased when used in combination with Methyclothiazide.
Gemtuzumab Ozogamicin Injection Gemtuzumab Ozogamicin Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Gemtuzumab ozogamicin.
Semaglutide Injection Semaglutide Injection The therapeutic efficacy of Semaglutide can be decreased when used in combination with Methyclothiazide.
Ertugliflozin Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Methyclothiazide.
Buprenorphine Injection Buprenorphine Injection The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Buprenorphine.
Apalutamide Apalutamide Methyclothiazide may increase the excretion rate of Apalutamide which could result in a lower serum level and potentially a reduction in efficacy.
Penicillamine Penicillamine The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Penicillamine.
Fostamatinib Fostamatinib The risk or severity of hypotension can be increased when Fostamatinib is combined with Methyclothiazide.
Baricitinib Baricitinib Methyclothiazide may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.
Lofexidine Lofexidine The therapeutic efficacy of Lofexidine can be increased when used in combination with Methyclothiazide.
Plazomicin Injection Plazomicin Injection Methyclothiazide may increase the excretion rate of Plazomicin which could result in a lower serum level and potentially a reduction in efficacy.
Stiripentol Stiripentol Methyclothiazide may increase the excretion rate of Stiripentol which could result in a lower serum level and potentially a reduction in efficacy.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Paclitaxel.
Prucalopride Prucalopride The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Prucalopride.
Magnesium Citrate Magnesium Citrate The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium citrate.
Acyclovir Ophthalmic Acyclovir Ophthalmic Methyclothiazide may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.
Cladribine Cladribine The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Cladribine.
Solriamfetol Solriamfetol Methyclothiazide may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.
Pitolisant Pitolisant Methyclothiazide may increase the excretion rate of Pitolisant which could result in a lower serum level and potentially a reduction in efficacy.
Calcium Acetate Calcium Acetate Methyclothiazide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
Viloxazine Viloxazine Methyclothiazide may increase the excretion rate of Viloxazine which could result in a lower serum level and potentially a reduction in efficacy.
Fenoprofen Fenoprofen The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenoprofen.
Indomethacin Indomethacin The therapeutic efficacy of Indomethacin can be decreased when used in combination with Methyclothiazide.
Mefenamic Acid Mefenamic Acid The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mefenamic acid.
Naproxen Naproxen The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naproxen.
Tolmetin Tolmetin The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolmetin.
Trazodone Trazodone The risk or severity of hyponatremia can be increased when Trazodone is combined with Methyclothiazide.
Isotretinoin Isotretinoin Methyclothiazide may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.
Sucralfate Sucralfate Methyclothiazide may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.
Hydroxyurea Hydroxyurea The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Hydroxyurea.
Floxuridine Floxuridine Methyclothiazide may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.
Phenobarbital Phenobarbital The risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Methyclothiazide.
Metaxalone Metaxalone Methyclothiazide may increase the excretion rate of Metaxalone which could result in a lower serum level and potentially a reduction in efficacy.
Methotrexate Injection Methotrexate Injection The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methotrexate.
Levorphanol Levorphanol The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Levorphanol.
Primidone Primidone The risk or severity of hypotension and orthostatic hypotension can be increased when Primidone is combined with Methyclothiazide.
Chlorpromazine Chlorpromazine Methyclothiazide may increase the excretion rate of Chlorpromazine which could result in a lower serum level and potentially a reduction in efficacy.
Diazepam Diazepam Methyclothiazide may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.
Oxazepam Oxazepam Methyclothiazide may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.
Flurazepam Flurazepam Methyclothiazide may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.
Clorazepate Clorazepate Methyclothiazide may increase the excretion rate of Clorazepic acid which could result in a lower serum level and potentially a reduction in efficacy.
Lorazepam Lorazepam Methyclothiazide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
Phenoxybenzamine Phenoxybenzamine The therapeutic efficacy of Phenoxybenzamine can be increased when used in combination with Methyclothiazide.
Carmustine Carmustine Methyclothiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Amantadine Amantadine Methyclothiazide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.
Codeine Codeine The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Codeine.
Bromocriptine Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Methyclothiazide.
Metaproterenol Metaproterenol Orciprenaline may increase the hypokalemic activities of Methyclothiazide.
Tranylcypromine Tranylcypromine Tranylcypromine may increase the orthostatic hypotensive activities of Methyclothiazide.
Phenelzine Phenelzine Phenelzine may increase the orthostatic hypotensive activities of Methyclothiazide.
Procarbazine Procarbazine Procarbazine may increase the orthostatic hypotensive activities of Methyclothiazide.
Tetracycline Tetracycline Methyclothiazide may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.
Thioguanine Thioguanine The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Tioguanine.
Thioridazine Thioridazine The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Thioridazine.
Bleomycin Bleomycin Methyclothiazide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Sulfadiazine Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Methyclothiazide.
Oxycodone Oxycodone The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxycodone.
Methadone Methadone The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Methadone.
Oxybutynin Oxybutynin The serum concentration of Methyclothiazide can be increased when it is combined with Oxybutynin.
Benztropine Benztropine Benzatropine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Colestipol Colestipol Colestipol can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Maprotiline Maprotiline Maprotiline may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Ibuprofen Ibuprofen The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ibuprofen.
Trihexyphenidyl Trihexyphenidyl The serum concentration of Methyclothiazide can be increased when it is combined with Trihexyphenidyl.
Orphenadrine Orphenadrine The serum concentration of Methyclothiazide can be increased when it is combined with Orphenadrine.
Azathioprine Azathioprine Methyclothiazide may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.
Methylphenidate Methylphenidate Methyclothiazide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.
Amoxapine Amoxapine The serum concentration of Methyclothiazide can be increased when it is combined with Amoxapine.
Sulfasalazine Sulfasalazine The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sulfasalazine.
Hydrocortisone Hydrocortisone The risk or severity of electrolyte imbalance can be increased when Hydrocortisone is combined with Methyclothiazide.
Lomustine Lomustine The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Lomustine.
Doxorubicin Doxorubicin The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Doxorubicin.
Cytarabine Cytarabine The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Cytarabine.
Mechlorethamine Mechlorethamine The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Mechlorethamine.
Dactinomycin Dactinomycin The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Dactinomycin.
Phenazopyridine Phenazopyridine Methyclothiazide may increase the excretion rate of Phenazopyridine which could result in a lower serum level and potentially a reduction in efficacy.
Carbamazepine Carbamazepine The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carbamazepine.
Methyldopa Methyldopa The therapeutic efficacy of Methyldopa can be increased when used in combination with Methyclothiazide.
Clonidine Clonidine The therapeutic efficacy of Clonidine can be increased when used in combination with Methyclothiazide.
Prazosin Prazosin The therapeutic efficacy of Prazosin can be increased when used in combination with Methyclothiazide.
Hydralazine Hydralazine The therapeutic efficacy of Hydralazine can be increased when used in combination with Methyclothiazide.
Cimetidine Cimetidine Methyclothiazide may increase the excretion rate of Cimetidine which could result in a lower serum level and potentially a reduction in efficacy.
Warfarin Warfarin Methyclothiazide may increase the excretion rate of Warfarin which could result in a lower serum level and potentially a reduction in efficacy.
Clonazepam Clonazepam Methyclothiazide may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.
Promethazine Promethazine Promethazine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Meclofenamate Meclofenamate The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid.
Daunorubicin Daunorubicin The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Daunorubicin.
Nitrofurantoin Nitrofurantoin Methyclothiazide may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.
Methenamine Methenamine The therapeutic efficacy of Methenamine can be decreased when used in combination with Methyclothiazide.
Digoxin Digoxin Methyclothiazide may increase the hypokalemic activities of Digoxin.
Chloroquine Chloroquine Methyclothiazide may increase the excretion rate of Chloroquine which could result in a lower serum level and potentially a reduction in efficacy.
Quinine Quinine The therapeutic efficacy of Quinine can be decreased when used in combination with Methyclothiazide.
Calcitriol Calcitriol The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Calcitriol.
Triamterene Triamterene The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Triamterene.
Lactulose Lactulose The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lactulose.
Sulfinpyrazone Sulfinpyrazone The therapeutic efficacy of Sulfinpyrazone can be decreased when used in combination with Methyclothiazide.
Chlorothiazide Chlorothiazide The therapeutic efficacy of Chlorothiazide can be increased when used in combination with Methyclothiazide.
Chlorthalidone Chlorthalidone The therapeutic efficacy of Chlorthalidone can be increased when used in combination with Methyclothiazide.
Metolazone Metolazone The therapeutic efficacy of Metolazone can be increased when used in combination with Methyclothiazide.
Secobarbital Secobarbital The risk or severity of hypotension and orthostatic hypotension can be increased when Secobarbital is combined with Methyclothiazide.
Desipramine Desipramine Desipramine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Amitriptyline Amitriptyline Amitriptyline may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Imipramine Imipramine Methyclothiazide may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Probenecid Probenecid The therapeutic efficacy of Probenecid can be decreased when used in combination with Methyclothiazide.
Quinidine Quinidine Quinidine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Procainamide Procainamide Methyclothiazide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.
Isoniazid Isoniazid Methyclothiazide may increase the excretion rate of Isoniazid which could result in a lower serum level and potentially a reduction in efficacy.
Pyrazinamide Pyrazinamide Methyclothiazide may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.
Disopyramide Disopyramide The therapeutic efficacy of Disopyramide can be decreased when used in combination with Methyclothiazide.
Mitomycin Mitomycin The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Mitomycin.
Butabarbital Butabarbital Methyclothiazide may increase the excretion rate of Butabarbital which could result in a lower serum level and potentially a reduction in efficacy.
Liothyronine Liothyronine Methyclothiazide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.
Methimazole Methimazole Methyclothiazide may increase the excretion rate of Methimazole which could result in a lower serum level and potentially a reduction in efficacy.
Propylthiouracil Propylthiouracil The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Propylthiouracil.
Chlorpropamide Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methyclothiazide.
Tolbutamide Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methyclothiazide.
Tolazamide Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Methyclothiazide.
Dextromethorphan Dextromethorphan The serum concentration of Methyclothiazide can be increased when it is combined with Dextromethorphan.
Baclofen Baclofen Methyclothiazide may increase the excretion rate of Baclofen which could result in a lower serum level and potentially a reduction in efficacy.
Doxylamine Doxylamine The serum concentration of Methyclothiazide can be increased when it is combined with Doxylamine.
Cyproheptadine Cyproheptadine The serum concentration of Methyclothiazide can be increased when it is combined with Cyproheptadine.
Brompheniramine Brompheniramine The serum concentration of Methyclothiazide can be increased when it is combined with Brompheniramine.
Ethambutol Ethambutol Methyclothiazide may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be increased when used in combination with Methyclothiazide.
Chlorzoxazone Chlorzoxazone Methyclothiazide may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.
Pyridoxine Pyridoxine Methyclothiazide may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.
Folic Acid Folic Acid Methyclothiazide may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The therapeutic efficacy of Propranolol can be increased when used in combination with Methyclothiazide.
Minoxidil Minoxidil The therapeutic efficacy of Minoxidil can be increased when used in combination with Methyclothiazide.
Nortriptyline Nortriptyline The serum concentration of Methyclothiazide can be increased when it is combined with Nortriptyline.
Spironolactone Spironolactone The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Spironolactone.
Amphotericin B Injection Amphotericin B Injection The risk or severity of electrolyte imbalance can be increased when Methyclothiazide is combined with Amphotericin B.
Mercaptopurine Mercaptopurine The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Mercaptopurine.
Phytonadione Phytonadione Methyclothiazide may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.
Nadolol Nadolol The therapeutic efficacy of Nadolol can be increased when used in combination with Methyclothiazide.
Butorphanol Injection Butorphanol Injection The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Butorphanol.
Nalbuphine Injection Nalbuphine Injection The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nalbuphine.
Cholestyramine Resin Cholestyramine Resin Cholestyramine can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Allopurinol Allopurinol The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Methyclothiazide.
Flavoxate Flavoxate Flavoxate may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Papaverine Papaverine The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Fluorouracil.
Colchicine Colchicine The therapeutic efficacy of Colchicine can be decreased when used in combination with Methyclothiazide.
Cefaclor Cefaclor Methyclothiazide may increase the excretion rate of Cefaclor which could result in a lower serum level and potentially a reduction in efficacy.
Cefadroxil Cefadroxil Methyclothiazide may increase the excretion rate of Cefadroxil which could result in a lower serum level and potentially a reduction in efficacy.
Cephalexin Cephalexin Methyclothiazide may increase the excretion rate of Cephalexin which could result in a lower serum level and potentially a reduction in efficacy.
Dacarbazine Dacarbazine Methyclothiazide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Calcitonin Salmon Injection Calcitonin Salmon Injection Methyclothiazide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
Pyrantel Pyrantel Methyclothiazide may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.
Thiotepa Injection Thiotepa Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Thiotepa.
Captopril Captopril The therapeutic efficacy of Captopril can be increased when used in combination with Methyclothiazide.
Dipyridamole Dipyridamole The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dipyridamole.
Isoxsuprine Isoxsuprine The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isoxsuprine.
Vinblastine Vinblastine The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Vinblastine.
Ethacrynic Acid Ethacrynic Acid The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Etacrynic acid.
Metoprolol Metoprolol The therapeutic efficacy of Metoprolol can be increased when used in combination with Methyclothiazide.
Aspirin Aspirin Acetylsalicylic acid may decrease the excretion rate of Methyclothiazide which could result in a higher serum level.
Salsalate Salsalate The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salsalate.
Chlorambucil Chlorambucil The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Chlorambucil.
Alprazolam Alprazolam Methyclothiazide may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.
Temazepam Temazepam Methyclothiazide may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.
Triazolam Triazolam Methyclothiazide may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.
Dicyclomine Dicyclomine Dicyclomine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Hyoscyamine Hyoscyamine The serum concentration of Methyclothiazide can be increased when it is combined with Hyoscyamine.
Propantheline Propantheline Propantheline may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Trimethoprim Trimethoprim Methyclothiazide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.
Diltiazem Diltiazem The therapeutic efficacy of Diltiazem can be increased when used in combination with Methyclothiazide.
Nifedipine Nifedipine Methyclothiazide may increase the excretion rate of Nifedipine which could result in a lower serum level and potentially a reduction in efficacy.
Timolol Timolol The therapeutic efficacy of Timolol can be increased when used in combination with Methyclothiazide.
Verapamil Verapamil Methyclothiazide may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Atenolol Atenolol The therapeutic efficacy of Atenolol can be increased when used in combination with Methyclothiazide.
Pindolol Pindolol The therapeutic efficacy of Pindolol can be increased when used in combination with Methyclothiazide.
Cisplatin Injection Cisplatin Injection Methyclothiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Diflunisal Diflunisal The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diflunisal.
Piroxicam Piroxicam The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Piroxicam.
Bumetanide Bumetanide Methyclothiazide may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
Streptozocin Streptozocin The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Streptozocin.
Etoposide Etoposide The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Etoposide.
Glyburide Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Methyclothiazide.
Glipizide Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Methyclothiazide.
Indapamide Indapamide The therapeutic efficacy of Indapamide can be increased when used in combination with Methyclothiazide.
Amoxicillin Amoxicillin Methyclothiazide may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.
Oxacillin Injection Oxacillin Injection Methyclothiazide may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.
Pentoxifylline Pentoxifylline Methyclothiazide may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.
Pentamidine Injection Pentamidine Injection The therapeutic efficacy of Pentamidine can be decreased when used in combination with Methyclothiazide.
Ceftriaxone Injection Ceftriaxone Injection Methyclothiazide may increase the excretion rate of Ceftriaxone which could result in a lower serum level and potentially a reduction in efficacy.
Labetalol Labetalol The therapeutic efficacy of Labetalol can be increased when used in combination with Methyclothiazide.
Auranofin Auranofin Methyclothiazide may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.
Leuprolide Injection Leuprolide Injection Methyclothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Gemfibrozil Gemfibrozil Methyclothiazide may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.
Guanabenz Guanabenz The therapeutic efficacy of Guanabenz can be increased when used in combination with Methyclothiazide.
Ceftazidime Injection Ceftazidime Injection Methyclothiazide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.
Ketoprofen Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Methyclothiazide.
Cefotetan Injection Cefotetan Injection Methyclothiazide may increase the excretion rate of Cefotetan which could result in a lower serum level and potentially a reduction in efficacy.
Enalapril Enalapril The therapeutic efficacy of Enalapril can be increased when used in combination with Methyclothiazide.
Flurbiprofen Flurbiprofen The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flurbiprofen.
Amiodarone Amiodarone The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amiodarone.
Aztreonam Injection Aztreonam Injection Methyclothiazide may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.
Buspirone Buspirone Methyclothiazide may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.
Ciprofloxacin Ciprofloxacin Methyclothiazide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.
Mesalamine Mesalamine The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mesalazine.
Diclofenac Diclofenac The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diclofenac.
Fluoxetine Fluoxetine The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Methyclothiazide.
Nimodipine Nimodipine The therapeutic efficacy of Nimodipine can be increased when used in combination with Methyclothiazide.
Interferon Alfa-2b Injection Interferon Alfa-2b Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfa-2b.
Clozapine Clozapine Methyclothiazide may increase the excretion rate of Clozapine which could result in a lower serum level and potentially a reduction in efficacy.
Estazolam Estazolam Methyclothiazide may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.
Idarubicin Idarubicin The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Idarubicin.
Didanosine Didanosine Methyclothiazide may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.
Fludarabine Injection Fludarabine Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Fludarabine.
Pentostatin Injection Pentostatin Injection Methyclothiazide may increase the excretion rate of Pentostatin which could result in a lower serum level and potentially a reduction in efficacy.
Benazepril Benazepril The therapeutic efficacy of Benazepril can be increased when used in combination with Methyclothiazide.
Etodolac Etodolac The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etodolac.
Felodipine Felodipine The therapeutic efficacy of Felodipine can be increased when used in combination with Methyclothiazide.
Fosinopril Fosinopril The therapeutic efficacy of Fosinopril can be increased when used in combination with Methyclothiazide.
Nabumetone Nabumetone The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nabumetone.
Quinapril Quinapril The therapeutic efficacy of Quinapril can be increased when used in combination with Methyclothiazide.
Ramipril Ramipril The therapeutic efficacy of Ramipril can be increased when used in combination with Methyclothiazide.
Amlodipine Amlodipine The therapeutic efficacy of Amlodipine can be increased when used in combination with Methyclothiazide.
Teniposide Injection Teniposide Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Teniposide.
Lisinopril Lisinopril The therapeutic efficacy of Lisinopril can be increased when used in combination with Methyclothiazide.
Oxaprozin Oxaprozin The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxaprozin.
Sotalol Sotalol The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sotalol.
Bisoprolol Bisoprolol The therapeutic efficacy of Bisoprolol can be increased when used in combination with Methyclothiazide.
Doxazosin Doxazosin The therapeutic efficacy of Doxazosin can be increased when used in combination with Methyclothiazide.
Terazosin Terazosin The therapeutic efficacy of Terazosin can be increased when used in combination with Methyclothiazide.
Isradipine Isradipine The therapeutic efficacy of Isradipine can be increased when used in combination with Methyclothiazide.
Venlafaxine Venlafaxine Methyclothiazide may increase the excretion rate of Venlafaxine which could result in a lower serum level and potentially a reduction in efficacy.
Fluvoxamine Fluvoxamine The risk or severity of hyponatremia can be increased when Fluvoxamine is combined with Methyclothiazide.
Nefazodone Nefazodone The risk or severity of hyponatremia can be increased when Nefazodone is combined with Methyclothiazide.
Lamotrigine Lamotrigine Lamotrigine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Losartan Losartan The therapeutic efficacy of Losartan can be increased when used in combination with Methyclothiazide.
Valacyclovir Valacyclovir Methyclothiazide may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.
Tramadol Tramadol The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tramadol.
Vinorelbine Injection Vinorelbine Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Vinorelbine.
Carboplatin Injection Carboplatin Injection Methyclothiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.
Moexipril Moexipril The therapeutic efficacy of Moexipril can be increased when used in combination with Methyclothiazide.
Ifosfamide Injection Ifosfamide Injection Methyclothiazide may increase the excretion rate of Ifosfamide which could result in a lower serum level and potentially a reduction in efficacy.
Nicardipine Nicardipine The therapeutic efficacy of Nicardipine can be increased when used in combination with Methyclothiazide.
Bupropion Bupropion Methyclothiazide may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.
Ticlopidine Ticlopidine Methyclothiazide may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.
Metformin Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Methyclothiazide.
Dalteparin Injection Dalteparin Injection The therapeutic efficacy of Dalteparin can be decreased when used in combination with Methyclothiazide.
Nisoldipine Nisoldipine The therapeutic efficacy of Nisoldipine can be increased when used in combination with Methyclothiazide.
Lamivudine Lamivudine Methyclothiazide may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.
Amifostine Injection Amifostine Injection The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amifostine.
Acarbose Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Methyclothiazide.
Glimepiride Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Methyclothiazide.
Gemcitabine Injection Gemcitabine Injection Methyclothiazide may increase the excretion rate of Gemcitabine which could result in a lower serum level and potentially a reduction in efficacy.
Docetaxel Injection Docetaxel Injection The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Docetaxel.
Cidofovir Injection Cidofovir Injection Methyclothiazide may increase the excretion rate of Cidofovir which could result in a lower serum level and potentially a reduction in efficacy.
Meropenem Injection Meropenem Injection Methyclothiazide may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.
Clomipramine Clomipramine Methyclothiazide may increase the excretion rate of Clomipramine which could result in a lower serum level and potentially a reduction in efficacy.
Fosfomycin Fosfomycin Methyclothiazide may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.
Trandolapril Trandolapril The therapeutic efficacy of Trandolapril can be increased when used in combination with Methyclothiazide.
Topiramate Topiramate The risk or severity of hypokalemia can be increased when Methyclothiazide is combined with Topiramate.
Valsartan Valsartan The therapeutic efficacy of Valsartan can be increased when used in combination with Methyclothiazide.
Insulin Lispro Injection Insulin Lispro Injection The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Methyclothiazide.
Pramipexole Pramipexole Methyclothiazide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.
Carvedilol Carvedilol The therapeutic efficacy of Carvedilol can be increased when used in combination with Methyclothiazide.
Nilutamide Nilutamide Methyclothiazide may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.
Flutamide Flutamide Methyclothiazide may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.
Selegiline Selegiline Selegiline may increase the orthostatic hypotensive activities of Methyclothiazide.
Sertraline Sertraline The risk or severity of hyponatremia can be increased when Sertraline is combined with Methyclothiazide.
Irbesartan Irbesartan The therapeutic efficacy of Irbesartan can be increased when used in combination with Methyclothiazide.
Tamsulosin Tamsulosin Methyclothiazide may increase the excretion rate of Tamsulosin which could result in a lower serum level and potentially a reduction in efficacy.
Ropinirole Ropinirole The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ropinirole.
Quetiapine Quetiapine Methyclothiazide may increase the excretion rate of Quetiapine which could result in a lower serum level and potentially a reduction in efficacy.
Cetirizine Cetirizine Methyclothiazide may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.
Paroxetine Paroxetine The risk or severity of hyponatremia can be increased when Paroxetine is combined with Methyclothiazide.
Tolcapone Tolcapone Methyclothiazide may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.
Citalopram Citalopram The risk or severity of hyponatremia can be increased when Citalopram is combined with Methyclothiazide.
Capecitabine Capecitabine Methyclothiazide may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.
Abacavir Abacavir Methyclothiazide may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
Sildenafil Sildenafil The risk or severity of hypotension can be increased when Sildenafil is combined with Methyclothiazide.
Pioglitazone Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methyclothiazide.
Celecoxib Celecoxib The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Celecoxib.
Rosiglitazone Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methyclothiazide.
Tolterodine Tolterodine Tolterodine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Thalidomide Thalidomide The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Thalidomide.
Oseltamivir Oseltamivir Methyclothiazide may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.
Colesevelam Colesevelam Colesevelam can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Balsalazide Balsalazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Balsalazide.
Nateglinide Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Methyclothiazide.
Rabeprazole Rabeprazole Methyclothiazide may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.

* This branded product is no longer on the market. Generic alternatives may be available.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists